Multicentre, Randomised, Open-label Study Comparing the Tolerability and Viral Reduction of the Combination of IFN Alpha-2b XL + Ribavirin Versus Peg IFN Alpha-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4.
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2013
At a glance
- Drugs Interferon alpha-2b (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms COAT-IFN
- 07 Jun 2017 Biomarkers information updated
- 18 Sep 2013 Planned end date changed from 1 Jun 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 13 Nov 2012 Interim results presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History